Study S000148

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Master Protocol Clinical Trial to Investigate the Efficacy and Safety of HRS-4729 Injection and HRS9531 Injection in Adult Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

ClinicalTrials.gov record

Registration

Registration: NCT07660848
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 160
Start: 2026-08-14
Primary completion: 2028-03
Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions: DRUG:HRS-4729 Injection; DRUG:HRS9531 Injection; DRUG:HRS-4729 Injection Placebo; DRUG:HRS9531 Injection Placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Percent Change from Baseline in Liver Fat Content by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) [Baseline, Week 32]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.